NCT01076751终止不适用
Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Sanofi
- 入组人数
- 82
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
Primary Objective:
- Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression
Secondary Objective:
- Describe treatment patterns
- Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others
- Describe economic and patient-reported outcomes
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Overall survival
时间窗: At Month 12 or death
次要结局
- Sequence of treatment in second-line, third-line(At Month 6 (+/- 2 months), Month 12 or death)
- Characteristics and outcomes of patients who receive second-line taxane-based treatment compared to others(At baseline, Month 6 (+/- 2 months), Month 12 or death)
- Indicators of health care resource utilization(At baseline, Month 6 (+/- 2 months), Month 12 or death)
- Quality of life(At baseline, Month 6 (+/- 2 months) or Month 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration TrialHead and Neck NeoplasmsNCT00995293Sanofi240
终止
2 期
Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT00378573Sanofi17
已完成
3 期
Docetaxel in Breast CancerBreast CancerNCT00312208Sanofi3,299
招募中
不适用
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer PatientsHormone Sensitive Prostate CancerMetastatic TumorProstate CancerNCT06473259Santa Chiara Hospital3,000
已完成
1 期
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)Castrate-Resistant Prostate CancerNCT01234025Ionis Pharmaceuticals, Inc.113